12-1-9　ⓔ文献

  1. D’Amico G, Garcia–Tsao G, et al: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol, 2006; 44: 217–231.

  2. Ripoll C, Groszmann R, et al: Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology, 2007; 133: 481–488.

  3. Wong F, Liu P, et al: Sodium homeostasis with chronic sodium loading in preascitic cirrhosis. Gut, 2001; 49: 847–851.

  4. Schrier RW, Arroyo V, et al: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology, 1988; 8: 1151–1157.

  5. Wiest R, Groszmann RJ: The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology, 2002; 35: 478–491.

  6. Runyon BA, AASLD: Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology, 2013; 57: 1651–1653.

  7. European Association for the Study of the Liver: EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol, 2010; 53: 397–417.

  8. Gines P, Cardenas A, et al: Management of cirrhosis and ascites. N Engl J Med, 2004; 350: 1646–1654.

  9. Planas R, Balleste B, et al: Natural history of decompensated hepatitis C virus–related cirrhosis. A study of 200 patients. J Hepatol, 2004; 40: 823–830.

  10. Garcia–Tsao G, Lee FY, et al: Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology, 1995; 108: 1835–1841.

  11. Fernandez J, Tandon P, et al: Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology, 2016; 63: 2019–2031.

  12. Wiest R, Krag A, et al: Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut, 2012; 61: 297–310.

  13. Tito L, Rimola A, et al: Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology, 1988; 8: 27–31.

  14. Moore KP, Wong F, et al: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology, 2003; 38: 258–266.

  15. Sakaida I, Kawazoe S, et al: Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double–blind, placebo–controlled trial. Hepatol Res, 2014; 44: 73–82.

  16. Gines P, Arroyo V, et al: Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med, 1991; 325: 829–835.

  17. Bernardi M, Caraceni P, et al: Albumin infusion in patients undergoing large–volume paracentesis: a meta–analysis of randomized trials. Hepatology, 2012; 55: 1172–1181.